Liu, Mengguo <br/><br/>
Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway.  [electronic resource] 

 -  Clinics (Sao Paulo, Brazil)  Apr 2015 
 - 250-6 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1980-5322 
<br/><br/><label>Standard No.: </label>10.6061/clinics/2015(04)06  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abietanes--pharmacology<br/>Adult<br/>Anti-Inflammatory Agents, Non-Steroidal--pharmacology<br/>Blotting, Far-Western<br/>Cell Migration Assays<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cells, Cultured--drug effects<br/>Collagen Type I--analysis<br/>Collagen Type III--analysis<br/>Enzyme Activation--drug effects<br/>Extracellular Signal-Regulated MAP Kinases--drug effects<br/>Female<br/>Fluorescent Antibody Technique<br/>Humans<br/>Interleukin-17--analysis<br/>Male<br/>Middle Aged<br/>Muscle, Smooth, Vascular--drug effects<br/>Myocytes, Smooth Muscle--drug effects<br/>Reproducibility of Results<br/>Salvia miltiorrhiza--chemistry<br/>Scleroderma, Systemic--drug therapy<br/>Statistics, Nonparametric<br/>Time Factors